HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track

You may also be interested in...

Wyeth OTC loratadine

Company says it holds "first to file" ANDA status for orally disintegrating loratadine (Schering's Claritin Reditabs). Wyeth also has a pending 505(b)(2) application for OTC sale of the product. Firm recently told analysts Alavert launch would not be sidelined for six months by exclusivity issues (1"The Tan Sheet" Oct. 28, 2002, p. 4)...

Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval

Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy

Medtech Denorex “Deep Down Dandruff Relief” Ads Debuting In November

Medtech Products will launch a multi-million-dollar ad campaign in November to reacquaint dandruff sufferers with Denorex medicated shampoos and conditioners

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts